Paclitaxel is a chemotherapeutic agent widely used for treating
carcinomas. Patients receiving
paclitaxel often develop
neuropathic pain and have a reduced quality of life which hinders the use of this life-saving
drug. In this study, we determined the role of
GABA transporters in the genesis of
paclitaxel-induced
neuropathic pain using behavioral tests, electrophysiology, and biochemical techniques. We found that tonic
GABA receptor activities in the spinal dorsal horn were reduced in rats with
neuropathic pain induced by
paclitaxel. In normal controls, tonic
GABA receptor activities were mainly controlled by the
GABA transporter GAT-1 but not GAT-3. In the spinal dorsal horn, GAT-1 was expressed at presynaptic terminals and astrocytes while GAT-3 was only expressed in astrocytes. In rats with
paclitaxel-induced
neuropathic pain, the
protein expression of GAT-1 was increased while GAT-3 was decreased. This was concurrently associated with an increase in global
GABA uptake. The
paclitaxel-induced attenuation of GABAergic tonic inhibition was ameliorated by blocking GAT-1 but not GAT-3 transporters.
Paclitaxel-induced
neuropathic pain was significantly attenuated by the
intrathecal injection of a GAT-1 inhibitor. These findings suggest that targeting GAT-1 transporters for reversing disinhibition in the spinal dorsal horn may be a useful approach for treating
paclitaxel-induced
neuropathic pain. Patients receiving
paclitaxel for
cancer therapy often develop
neuropathic pain and have a reduced quality of life. In this study, we demonstrated that animals treated with
paclitaxel develop
neuropathic pain, have enhancements of
GABA transporter-1
protein expression and global
GABA uptake, as well as suppression of GABAergic tonic inhibition in the spinal dorsal horn. Pharmacological inhibition of
GABA transporter-1 ameliorates the
paclitaxel-induced suppression of GABAergic tonic inhibition and
neuropathic pain. Thus, targeting GAT-1 transporters for reversing GABAergic disinhibition in the spinal dorsal horn could be a useful approach for treating
paclitaxel-induced
neuropathic pain.